{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:42:05Z","timestamp":1771566125465,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.semarthrit.2022.152057","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T01:58:23Z","timestamp":1656467903000},"page":"152057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout"],"prefix":"10.1016","volume":"56","author":[{"given":"Ruth","family":"Topless","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siamak","family":"Noorbaloochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony R","family":"Merriman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3485-0006","authenticated-orcid":false,"given":"Jasvinder A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.semarthrit.2022.152057_bib0001","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheumatol"},{"issue":"10055","key":"10.1016\/j.semarthrit.2022.152057_bib0002","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"Dalbeth","year":"2016","journal-title":"Lancet North Am Ed"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152057_bib0003","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1136\/ard.2010.144022","article-title":"Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials","volume":"70","author":"Singh","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152057_bib0004","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3899\/jrheum.110271","article-title":"Patient-reported outcomes in chronic gout: a report from OMERACT 10","volume":"38","author":"Singh","year":"2011","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152057_bib0005","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/ard.2007.081604","article-title":"Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans","volume":"67","author":"Singh","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152057_bib0006","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/rheumatology\/kem150","article-title":"Is gout associated with reduced quality of life? A case-control study","volume":"46","author":"Roddy","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152057_bib0007","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152057_bib0008","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":"Quality of life and disability in patients with treatment-failure gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152057_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PROM.S8310","article-title":"Gout disease-specific quality of life and the association with gout characteristics","volume":"2010","author":"Hirsch","year":"2010","journal-title":"Patient Relat Outcome Meas"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152057_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3111\/13696998.2010.540874","article-title":"Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy","volume":"14","author":"Edwards","year":"2011","journal-title":"J Med Econ"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152057_bib0011","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s10067-015-3039-2","article-title":"You want to get on with the rest of your life\": a qualitative study of health-related quality of life in gout","volume":"35","author":"Chandratre","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152057_bib0012","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/ar4281","article-title":"Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR)","volume":"15","author":"Scire","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152057_bib0013","first-page":"620","article-title":"The health assessment questionnaire disability index is a valid measure of physical function in gout","volume":"26","author":"Taylor","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"10156","key":"10.1016\/j.semarthrit.2022.152057_bib0014","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152057_bib0015","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/rheumatology\/keq346","article-title":"Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout","volume":"50","author":"Khanna","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"23","key":"10.1016\/j.semarthrit.2022.152057_bib0016","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152057_bib0017","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152057_bib0018","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152057_bib0019","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152057_bib0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6-month study of allopurinol safety in gout: the LASSO study","volume":"45","author":"Becker","year":"2015","journal-title":"Semin Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152057_bib0021","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152057_bib0022","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152057_bib0023","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152057_bib0024","series-title":"The anxiety disease","author":"Sheehan","year":"1983"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152057_bib0025","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/rheumatology\/16.4.257","article-title":"Measurement of functional capacity with visual analogue scales","volume":"16","author":"Scott","year":"1977","journal-title":"Rheumatol Rehabil"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152057_bib0026","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2022.152057_bib0027","series-title":"R: a language and environment for statistical computing","year":"2020"},{"key":"10.1016\/j.semarthrit.2022.152057_bib0028","series-title":"RStudio: integrated development for R","year":"2020"},{"key":"10.1016\/j.semarthrit.2022.152057_bib0029","series-title":"Ggplot2: elegant graphics for data analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.semarthrit.2022.152057_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v082.i13","article-title":"lmerTest package: tests in linear mixed effects models","volume":"82","author":"Kuznetsova","year":"2017","journal-title":"J Stat Softw"},{"key":"10.1016\/j.semarthrit.2022.152057_bib0031","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1477-7525-10-117","article-title":"Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey","volume":"10","author":"Khanna","year":"2012","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152057_bib0032","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2017.12.005","article-title":"Health-related quality of life in gout in primary care: baseline findings from a cohort study","volume":"48","author":"Chandratre","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152057_bib0033","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3899\/jrheum.080506","article-title":"Evaluation of an instrument assessing influence of Gout on health-related quality of life","volume":"35","author":"Hirsch","year":"2008","journal-title":"J Rheumatol"},{"issue":"14","key":"10.1016\/j.semarthrit.2022.152057_bib0034","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","article-title":"Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials","volume":"32","author":"Wortmann","year":"2010","journal-title":"Clin Ther"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152057_bib0035","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152057_bib0036","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152057_bib0037","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/annrheumdis-2011-200801","article-title":"Patient and provider barriers to effective management of gout in general practice: a qualitative study","volume":"71","author":"Spencer","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152057_bib0038","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar4524","article-title":"Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study","volume":"16","author":"Singh","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152057_bib0039","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1477-7525-10-117","article-title":"Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey","volume":"10","author":"Khanna","year":"2012","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152057_bib0040","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/rheumatology\/keq346","article-title":"Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout","volume":"50","author":"Khanna","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152057_bib0041","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3899\/jrheum.111375","article-title":"Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials","volume":"39","author":"Strand","year":"2012","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152057_bib0042","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","article-title":"Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis","volume":"43","author":"Kosinski","year":"2000","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152057_bib0043","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","article-title":"The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis","volume":"44","author":"Matcham","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152057_bib0044","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/acr.22392","article-title":"Clinically important changes in short form 36 health survey scales for use in rheumatoid arthritis clinical trials: the impact of low responsiveness","volume":"66","author":"Ward","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152057_bib0045","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/rheumatology\/ket265","article-title":"Health-related quality of life in gout: a systematic review","volume":"52","author":"Chandratre","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152057_bib0046","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/rheumatology\/kem246","article-title":"Tophaceous joint disease strongly predicts hand function in patients with gout","volume":"46","author":"Dalbeth","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152057_bib0047","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1136\/annrheumdis-2014-205671","article-title":"Development of a patient-reported outcome measure of tophus burden: the tophus impact questionnaire (TIQ-20)","volume":"74","author":"Aati","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152057_bib0048","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","article-title":"Treat-to-target (T2T) recommendations for gout","volume":"76","author":"Kiltz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152057_bib0049","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kep087","article-title":"Treating to target: a strategy to cure gout","volume":"48","author":"Perez-Ruiz","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152057_bib0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2019-215315","article-title":"2018 updated European league against rheumatism evidence-based recommendations for the diagnosis of gout","volume":"79","author":"Richette","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152057_bib0051","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","article-title":"Japanese society of G, nucleic acid M. Japanese guideline for the management of hyperuricemia and gout: second edition","volume":"30","author":"Yamanaka","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152057_bib0052","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","article-title":"The British society for rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152057_bib0053","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"2020 American college of rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152057_bib0054","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Clinical Guidelines committee of the American college of P. management of acute and recurrent gout: a clinical practice guideline from the American college of physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2022.152057_bib0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cct.2018.03.015","article-title":"Design and rationale for the veterans affairs \u201ccooperative study program 594 comparative effectiveness in gout: allopurinol vs. Febuxostat\u201d trial","volume":"68","author":"Timilsina","year":"2018","journal-title":"Contemp Clin Trials"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:09:54Z","timestamp":1758733794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222001081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":55,"alternative-id":["S0049017222001081"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152057","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152057"}}